This article is more than 5 years old. Information may no longer be current.

SculpSure receives FDA 510(k) marketing clearance for non-invasive lipolysis of the abdomen

Cynosure Inc. announced it has received 510(k) clearance from the FDA to market SculpSure for non-invasive lipolysis of the abdomen.

The FDA cleared SculpSure for non-invasive lipolysis of the flanks in May.

SculpSure noninvasively reduces fat by disrupting subcutaneous fat cells, according to a press release.

The device uses a 1060 nm laser, which can treat anatomical areas in approximately 25 minutes.

The technology is expected to launch in the United States later in 2015.

Source: www.cynosure.com